#Scinai Immunotherapeutics #CDMO #Israel Innovation Authority

Scinai Secures Israel Innovation Authority Grant for CDMO Expansion

Scinai Immunotherapeutics Ltd. has recently announced an exciting development that promises to enhance its position in the biopharmaceutical arena. This innovative firm, which trades on NASDAQ under the ticker SCNI, has received a non-dilutive grant from the Israel Innovation Authority (IIA) amounting to approximately NIS 809,000 (about $246,000). This financial boost will support two-thirds of a NIS 1.23 million ($373,000) project aimed at advancing Scinai's fill-and-finish capabilities within its growing contract development and manufacturing organization (CDMO), Scinai Bioservices.

The project is particularly critical as it addresses a considerable gap in the biotech sector, especially for early-stage companies in Israel that often encounter challenges in obtaining local, small-scale, and flexible GMP manufacturing services. The lack of such resources forces many of these firms to outsource their needs overseas, resulting in higher costs and lengthy lead times, issues that Scinai aims to rectify.

Meeting Industry Needs with Advanced Manufacturing

The grant from the IIA will enhance Scinai's ability to offer an advanced fill-and-finish system designed for sterile manufacturing, facilitating varied primary packaging formats with minimal reengineering. This flexibility allows for swift batch turnaround times and seamless transitions between different production campaigns, both of which are vital for a competitive edge in today’s fast-paced biopharma market.

The support from the IIA not only underscores Scinai's leadership in establishing Israel's biopharma manufacturing ecosystem but also highlights the importance of CDMO services. These services allow early-stage pharmaceutical and academic teams to maximize their limited resources effectively by accessing top-notch facilities, skilled personnel, and advanced manufacturing solutions without the burden of hefty capital investments.

Israel's biopharma sector, with over 300 companies, remains significantly underserved by full-service CDMOs. Recognizing this gap, Scinai has taken steps to fill the void by providing comprehensive end-to-end CDMO solutions. These services range from early-stage drug development processes all the way to GMP drug substance and product manufacturing, targeting clientele in Israel, the United States, and Europe.

Since the commencement of its CDMO operations in 2023, Scinai Bioservices has quickly established a reputation for high-quality manufacturing support. Located in Jerusalem, its cGMP facility is characterized by its collaborative approach and rapid project initiation capabilities. Clients value the personalized attention they receive, a quality that is often lost in larger CDMO operations.

Focused on Future Expansion

Amir Reichman, Scinai's CEO, expressed excitement regarding the grant, stating that it significantly validates Scinai Bioservices' evolving role in the local biopharma manufacturing landscape. The investment will enable a significant boost in the company’s fill-and-finish capacities, equipping them to offer a dependable, high-quality, and agile partnership to early-stage biotechnical firms, something they typically would find only with larger global competitors.